@FiercePharma: Japan's MHLW sets Sovaldi price, hep C competition heats up. FiercePharmaAsia article | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing this week: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. Story | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds. Report | Follow @CarlyHFierce
> Zydus Cadila's net profit jumped 46% in Q4, it reported. More
> Analysts who cover Orexigen ($OREX) are almost all saying "buy," despite the company's tumultuous week. Report
> Dr. Reddy's Laboratories ($RDY) has launched stroke-management drug Somazine in India. Report
> A U.S. judge rejected FedEx's ($FDX) bid to dismiss charges it conspired with "rogue" online drugstores. Report
Medical Device News
@FierceMedDev: Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M. More | Follow @FierceMedDev
@VarunSaxena2: Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Article | Follow @VarunSaxena2
@EmilyWFierce: OncoCyte ropes in $7M for cancer diagnostic R&D. FierceDiagnostics story | Follow @EmilyWFierce
> Data presented at cardiology conference show Abbott's MitraClip can cut arrhythmias in half. More
> Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Report
> Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M. Article
Biotech News
@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech
@JohnCFierce: Circassia snags a pair of asthma biotechs for $376M. Report | Follow @JohnCFierce
@DamianFierce: Wait did they just invent NantPharma for this deal? Is there a geneology chart for the NantFamily? Release | Follow @DamianFierce
> Soon-Shiong bets $90M on Sorrento's next-gen Abraxane with $1.2B on the line. Report
> Celladon halves its workforce to conserve cash after gene therapy meltdown. Story
> Racing a crowded field, Amgen says migraine drug looks promising in PhII. Article
And Finally... London's King's College Hospital is piloting a scheme whereby cancer patients undergoing chemotherapy treatments are given Apple Watches to manage their medication. More